Key Points
- CEO Amit Kumar bought 21,000 shares of Anixa Biosciences at $2.50 each, a $52,500 purchase that increased his direct stake by 3.44% to 630,812 shares.
- The stock was up 5.2% and opened at $2.61, while the company remains a small-cap biotech with a market value of about $88.8 million.
- Anixa recently reported a quarterly loss of $0.07 per share, beating analyst estimates of a $0.10 loss, while Wall Street’s consensus rating remains Hold with a $8.50 price target.
Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar acquired 21,000 shares of the company's stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average cost of $2.50 per share, with a total value of $52,500.00. Following the acquisition, the chief executive officer directly owned 630,812 shares of the company's stock, valued at $1,577,030. This trade represents a 3.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Anixa Biosciences Trading Up 5.2%
Shares of ANIX opened at $2.61 on Wednesday. Anixa Biosciences Inc has a 12-month low of $2.32 and a 12-month high of $5.46. The firm has a 50-day moving average price of $2.78 and a 200 day moving average price of $3.06. The firm has a market capitalization of $88.79 million, a P/E ratio of -8.42 and a beta of 0.59.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last announced its earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. Equities research analysts predict that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have weighed in on ANIX shares. Wall Street Zen lowered shares of Anixa Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, May 30th. D. Boral Capital reissued a "buy" rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday, April 8th. Citigroup reissued a "buy" rating on shares of Anixa Biosciences in a research note on Friday. Finally, HC Wainwright reissued a "buy" rating on shares of Anixa Biosciences in a research note on Friday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $8.50.
Get Our Latest Stock Report on Anixa Biosciences
Institutional Trading of Anixa Biosciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANIX. 683 Capital Management LLC acquired a new stake in Anixa Biosciences during the fourth quarter worth approximately $355,000. ExodusPoint Capital Management LP acquired a new stake in Anixa Biosciences during the fourth quarter worth approximately $293,000. Susquehanna International Group LLP raised its holdings in Anixa Biosciences by 378.4% during the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company's stock worth $265,000 after purchasing an additional 63,584 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Anixa Biosciences in the 4th quarter valued at $161,000. Finally, State Street Corp increased its holdings in shares of Anixa Biosciences by 32.0% in the 4th quarter. State Street Corp now owns 159,040 shares of the company's stock valued at $496,000 after acquiring an additional 38,540 shares during the period. Institutional investors and hedge funds own 29.13% of the company's stock.
About Anixa Biosciences
(
Get Free Report)
Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
